MedTrace Logo

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

NCT04355806 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2020-04-21

No results posted yet for this study

Summary

This project is to assess the immunogenicity, safety and overall survival impact of intramuscular injection of trivalent influenza vaccine in non-small cell lung cancer (NSCLC) patients with PD-1/PD-L1 inhibitor treatment.

Conditions

  • Non Small Cell Lung Cancer
  • Influenza Vaccine

Interventions

DRUG

PD-1/PD-L1 inhibitors

Including nivolumab, pembrolizumab, atezolizumab, and durvalumab, et al.

BIOLOGICAL

Inactivated trivalent influenza vaccine

Including two type A viruses, H1N1 and H3N2, and one type B virus, B/Brisbane.

Sponsors & Collaborators

  • The University of Hong Kong

    collaborator OTHER

  • Shanghai Pulmonary Hospital, Shanghai, China

    lead OTHER

Principal Investigators

  • Yayi He, PhD, MD · Shanghai Pulmonary Hospital, Shanghai, China

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2022-12-31
Completion
2023-05-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04355806 on ClinicalTrials.gov